IL6 and COVID-19: Tocilizumab is a recombinant humanized monoclonal immunoglobulin G1 (IgG1)antibody that blocks interleukin-6 (IL-6) binding to its receptor, reducingdownstream inflammatory signaling.44 In two landmark RCTs, tocilizumab reduced mortality in hospitalizedadults with severe or critical COVID-19.45,46 Of the nine RCTs thatevaluated tocilizumab for COVID-19,45, , , , , , , –53 only the RECOVERY trialpermitted enrollment of pregnant people (n = 10, 0.2% of participants).45 Specific maternal and neonatal outcomes were not reported.